glp 1 shortage over NHS faces GLP-1 agonist until 'at least end of 2024' How GLP-1s Broke Healthcare Distribution

Its Dispovan syringes are among the leading single-use syringes used across hospitals and clinics in the country

empagliflozin) therapy Overweight or obese patients with an HbA1c above target despite regular use or inability to tolerate metformin All other patients with an HbA1c above target despite regular use or inability to tolerate metformin and vildagliptin In all patients with an HbA1c to target where a GLP1RA may be preferred to limit adverse effects from thiazolidinedione, sulfonylurea and/or insulin therapy (particularly weight gain and hypoglycaemia) Need to stop in GI illness as per sick day management plan Not registered for use: eGFR 10 years of age when clinically appropriate

Indianapolis, IN: Eli Lilly and Co

Professional liability considerations may differ from those associated with FDA-approved medications, and providers should maintain comprehensive documentation of treatment rationale and patient consent